Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Go back to Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 228.41 +0.81 (0.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $227.60 | 52 Week High | $333.65 | |||
| Open | $225.87 | 52 Week Low | $223.02 | |||
| Day High | $230.49 | P/E | 29.25 | |||
| Day Low | $225.51 | EPS | $7.81 | |||
| Volume | 599,036 | |||||
| Sagebrush Gold Ltd. (NASDAQ: SAGE) | Delayed: 8.68 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.68 | 52 Week High | $62.64 | |||
| Open | $8.68 | 52 Week Low | $26.28 | |||
| Day High | $8.68 | P/E | N/A | |||
| Day Low | $8.68 | EPS | $-0.94 | |||
| Volume | 163,741 | |||||
